Key Highlights

  • ARGX shares traded up 6.29% to $877.50, versus a prior close of $825.61.
  • Phase 3 ALKIVIA met its primary endpoint in myositis with a 15.4-point advantage and p=0.0011.
  • Positive Phase 2 celiac data offset an earlier Sjogren's trial halt.
  • RBC trimmed its target to $1,025 from $1,100 but kept Outperform.
  • Q3 results and a business update are due Oct. 22.

Myositis and Celiac Data Offset an Earlier Setback

argenx (NASDAQ:ARGX) shares traded up 6.29% to $877.50 as investors weighed positive Phase 3 ALKIVIA data in myositis and Phase 2 celiac results. ALKIVIA met its primary endpoint with a 15.4-point total improvement score advantage and a p-value of 0.0011.

The data offset an earlier halt of a Sjogren's trial. The rebound is outpacing a firmer healthcare sector.

RBC Sees Round-Tripping and Trims Its Target

RBC said the shares have been round tripping on pipeline news and a tough biotech tape, and that celiac may be undervalued. It trimmed its target to $1,025 from $1,100 but kept an Outperform rating. Consensus target is about $1,163.

Shares trade against a 52-week range of $661.85 to $1,072.75, near their average, with a market capitalization of about $55.00 billion.

Vyvgart Sales Anchor the Story

The Amsterdam-based company's lead product, Vyvgart, is the first approved FcRn blocker, and it generated about $4.2 billion in net product sales in 2025, up roughly 90%. Earnings per share are $27.73. The main risk remains concentration in a single drug franchise.

Thursday's Results and the ACR Presentation Are the Next Steps

Investors watch the Q3 results and business update on Oct. 22, followed by the late-breaking presentation at the ACR meeting on Nov. 11.